Literature DB >> 3343304

Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

A L Barry1, R N Jones.   

Abstract

For in vitro susceptibility tests with cefoperazone and sulbactam (a beta-lactamase inhibitor), 75/30-micrograms disks may be used with the interpretive zone size breakpoints that are currently used for 75-micrograms cefoperazone disks. For dilution tests, a 2:1 ratio of cefoperazone to sulbactam is recommended. For quality control purposes, MIC limits that are used to monitor cefoperazone tests were also applied to tests with the combination of drugs. For gram-negative control strains, zone size limits were calculated to be 1 mm smaller than those used for cefoperazone disks. To monitor the sulbactam portion of the combination, Acinetobacter calcoaceticus subsp. anitratus ATCC 43498 was selected; zones with 75/30-micrograms disks were 26 to 32 mm in diameter, and broth microdilution MICs ranged from 1.0/0.5 to 8.0/4.0 micrograms/ml. With cefoperazone alone, MICs for Acinetobacter calcoaceticus subsp. anitratus were 16 to 64 micrograms/ml and zones ranged from 14 to 18 mm in diameter. For anaerobic dilution tests, only Bacteroides thetaiotaomicron ATCC 29741 is recommended for cefoperazone-sulbactam; MICs ranged from 8.0/4.0 to 32/16 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3343304      PMCID: PMC266166          DOI: 10.1128/jcm.26.1.13-17.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.

Authors:  A L Barry; R N Jones; R R Packer
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

2.  In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

Authors:  R N Jones; A L Barry; R R Packer; W W Gregory; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

3.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

4.  Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

Authors:  A L Barry; T L Gavan; R N Jones; L W Ayers; P C Fuchs; E H Gerlach; C Thornsberry
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

5.  Synergistic activity of cefoperazone in combination with beta-lactamase inhibitors.

Authors:  K P Fu; H C Neu
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

6.  Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.

Authors:  M A Crosby; D W Gump
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

7.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

8.  Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.

Authors:  P C Appelbaum; M R Jacobs; S K Spangler; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.

Authors:  R N Jones; H W Wilson; C Thornsberry; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1985-11       Impact factor: 2.803

10.  Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.

Authors:  R N Jones; T L Gavan; A L Barry; C Thornsberry; D L Gibbs
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

View more
  10 in total

1.  Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  D J Hardy; A L Barry; P C Fuchs; E H Gerlach; J C McLaughlin; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

2.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Genetic diversity of the capsular polysaccharide C biosynthesis region of Bacteroides fragilis.

Authors:  L E Comstock; A Pantosti; D L Kasper
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

4.  Detection of resistance due to inducible beta-lactamase in Enterobacter aerogenes and Enterobacter cloacae.

Authors:  T W Huber; J S Thomas
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

5.  Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii.

Authors:  Sarunyou Chusri; Virasakdi Chongsuvivatwong; Jesabel I Rivera; Kachornsakdi Silpapojakul; Kamonnut Singkhamanan; Edward McNeil; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

6.  A survey of pathogens associated with Cyperus esculentus L (tiger nuts) tubers sold in a Ghanaian city.

Authors:  Patrick F Ayeh-Kumi; Patience B Tetteh-Quarcoo; Kwabena O Duedu; Akua S Obeng; Kantanka Addo-Osafo; Samuel Mortu; Richard H Asmah
Journal:  BMC Res Notes       Date:  2014-06-06

7.  Genetic characterization and in vitro activity of antimicrobial combinations of multidrug-resistant Acinetobacter baumannii from a general hospital in China.

Authors:  Fang Chen; Ling Wang; Min Wang; Yixin Xie; Xiaomeng Xia; Xianping Li; Yanhua Liu; Wei Cao; Tingting Zhang; Pengling Li; Min Yang
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

8.  Characterization of a New Mixture of Mono-Rhamnolipids Produced by Pseudomonas gessardii Isolated from Edmonson Point (Antarctica).

Authors:  Carmine Buonocore; Pietro Tedesco; Giovanni Andrea Vitale; Fortunato Palma Esposito; Rosa Giugliano; Maria Chiara Monti; Maria Valeria D'Auria; Donatella de Pascale
Journal:  Mar Drugs       Date:  2020-05-20       Impact factor: 5.118

9.  Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Siripen Kanchanasuwan; Narongdet Kositpantawong; Kamonnut Singkhamanan; Thanaporn Hortiwakul; Boonsri Charoenmak; Nwabor Ozioma F; Yohei Doi; Sarunyou Chusri
Journal:  Infect Drug Resist       Date:  2021-03-29       Impact factor: 4.003

10.  Carbapenem Resistance in Non-Fermentative Bacterial Species and in Enterobacteriaceae Isolates from Hospitalized Patients in Different Health-Care Settings.

Authors:  Mihaela Ileana Ionescu; Dan Stefan Neagoe; Claudia Chiorean; Loredana Dumitras; Aurelia Rus
Journal:  Clujul Med       Date:  2014-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.